Biofrontera (NASDAQ:BFRI) Earns “Buy” Rating from Benchmark

Biofrontera (NASDAQ:BFRI)‘s stock had its “buy” rating restated by equities researchers at Benchmark in a research note issued on Friday,Benzinga reports. They currently have a $7.00 target price on the stock.

Biofrontera Stock Up 2.6 %

Shares of NASDAQ BFRI traded up $0.02 during midday trading on Friday, hitting $0.72. The company had a trading volume of 117,628 shares, compared to its average volume of 1,007,359. Biofrontera has a twelve month low of $0.61 and a twelve month high of $4.04. The firm has a market capitalization of $4.01 million, a price-to-earnings ratio of -0.30 and a beta of 0.50. The business has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.10.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($1.19) by $0.07. The firm had revenue of $7.84 million during the quarter, compared to the consensus estimate of $9.02 million. Biofrontera had a negative return on equity of 652.37% and a negative net margin of 36.31%. On average, equities analysts forecast that Biofrontera will post -3.11 EPS for the current year.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.